

Mauritania

Population 2015

4.1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.84 (0.5–1.3)	21 (12–31)
Mortality (HIV+TB only)	0.14 (0.054–0.27)	3.5 (1.3–6.7)
Incidence (includes HIV+TB)	4.3 (2.8–6.2)	107 (69–152)
Incidence (HIV+TB only)	0.44 (0.27–0.66)	11 (6.6–16)
Incidence (MDR/RR-TB)**	0.15 (0–0.32)	3.7 (0–7.9)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.23 (0.064–0.4)	1.2 (0.32–2.1)	1.4 (0.38–2.5)
Males	0.31 (0.18–0.45)	2.6 (1.8–3.4)	2.9 (1.9–3.9)
Total	0.55 (0.34–0.75)	3.8 (2.8–4.7)	4.3 (2.8–6.2)

TB case notifications, 2015	
Total cases notified	2 352
Total new and relapse	2 329
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	77%
- % bacteriologically confirmed among pulmonary	82%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	54% (38–83)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.24 (0.13–0.4)

TB/HIV care in new and relapse TB patients, 2015		Number	(%)
Patients with known HIV-status who are HIV-positive			
- on antiretroviral therapy			

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			69 (0–140)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	21% (2.2–39)	
% notified tested for rifampicin resistance	12%	33%	297
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 24, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 13, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	70%	2 420
Previously treated cases, excluding relapse, registered in 2014	62%	13
HIV-positive TB cases, all types, registered in 2014		0
MDR/RR-TB cases started on second-line treatment in 2013	43%	7
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically